Diario del páncreas Acceso abierto

Abstracto

Nab-Paclitaxel Plus Gemcitabine Therapy after Novel Cell-Free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites Associated with Pancreatic Adenocarcinoma: A Case Report

Tetsuro Akashi, Yu Takamatsu, Kazuhide Matsumoto, Risa Hashimoto, Takehiro Takaoka, Mitsugu Tanii

Context Peritoneal dissemination is an important prognostic factor for patients with metastatic pancreatic adenocarcinoma. For an improved prognosis and quality of life, more effective treatment for ascites is necessary. Case report We describe a seventy-one-yearold Japanese man with pancreatic adenocarcinoma with malignant ascites who had responded to treatment with Nab-paclitaxel plus gemcitabine after novel cell-free and concentrated ascites reinfusion therapy. For ascites control, KM-CART was performed twice. After that, systemic chemotherapy was initiated. His performance status improved since KM-CART could control the refractory ascites, which allowed chemotherapy to be administered. As a result, the patient survived for 11 months and was able to live without hospitalization for most of this time. Conclusion KM-CART may be an effective treatment for refractory ascites associated with cancerous peritonitis of pancreatic adenocarcinoma.